HCI-005 breast cancer PDX

HCI-005 PDX: Human breast cancer-derived xenograft retains high fidelity to original tumour. Valuable resources for drug discovery and precision oncology.

Contributors

Inventor Institute
Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose The University of Utah Research Foundation
Cat. #: 162073
Cancer types: Breast cancer
Cancer Subtype: Multifocal Breast Carcinoma (Infiltrating Ductal Carcinoma and Ductal carcinoma in situ)
Gender: Female
Cancer Stage or Grade: Stage IV
Biopsy Site: Pleural Effusion Fluid
Patient ethnicity: Caucasian
Treatment History: Pretreated: Patient had undergone radiation therapy of breast (2001), spine (2005), and right hip (2007) and had the following systemic treatment priror to sample collection: doxorubicin+cylophosphamide (2001), tamoxifen (2001-2005), letrazole (2005-2006), zolendronic acid (2005-2010), fulvestrant (2006), capecitabine (2006-2008), exemestane (2008), trastuzumab (2008), and vinorebline (2008)
Primary citation: Guillen, et al. 2022. Nature Cancer. Feb; 3(2):232-250. PMID: 35221336
Product description: Human breast cancer patient-derived xenograft (PDX) model that retains high fidelity to original tumour, including spatial structure, intratumour heterogeneity, genomic features, tumour growth rate, metastatic patterns, and drug responses. These highly translatable PDX models can be used to more accurately assess therapeutic efficacy and predict patient responses in preclinical drug validation studies than traditional models. This panel of PDX models includes some of the deadliest forms of breast cancer such as drug-resistant, metastatic tumours, and endocrine-resistant estrogen receptor-positive (ER+) and human epidermal growth factor receptor positive (HER2+) tumours. Sample collected in 2008 from pleural effusion of Caucasian female, age 52 at time of collection with a primary diagnosis of mixed multicentric disease; IDC; and DCIS; 2001. Patient had no history of smoking, with clinical metastasis to lung and bone. Patient had undergone radiation therapy of breast (2001), spine (2005), and right hip (2007) and had the following systemic treatment priror to sample collection: doxorubicin+cylophosphamide (2001), tamoxifen (2001-2005), letrazole (2005-2006), zolendronic acid (2005-2010), fulvestrant (2006), capecitabine (2006-2008), exemestane (2008), trastuzumab (2008), and vinorebline (2008). Patient characteristics were as follows – ER status: positive, PR status: positive, HER2 status: primary tumour was positive and amiplified. PDX characteristics were ER positive, PR positive, and HER2 positive,mixed; not amplified. PDX information: PAM50 subtype is luminal B, partially estrogen dependent, PTEN positive by IHC, and shows metastasis to lung, lymph node, and peritoneum.
Initial handling information: Implant into the cleared inguinal mammary fat pad of female Immune-compromised mice (NOD.SCID). This is an ER+ tumour. Time to grow to 1cm: 5 months
Additional notes: Additional Information on PDX establishment: https://www.nature.com/articles/s43018-022-00337-6/figures/9
Mice Passaged: Yes
Engraftment Site: Cleared mammary fat pad
Sample Type: Pleural Effusion Fluid in matrigel
Host Strain: Immunocompromised mice NOD scid gamma (NSG) Jackson Laboratory 5557; NOD/scid, Jackson Laboratory 1303 or NOD rag gamma (NRG), Jackson Laboratory 7799
Histology: PAM50 subtype Luminal B
Production details: Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation.
References:

Tufail, et al. 2024. Journal of Translational Med. Jan 3:22(1):15. PMID: 38172946

Bhattacharya, et al. 2023. Journal of Experimental & Clinical Cancer Research. Dec 16:42(1):343. PMID: 38102637

Prekovic, et al. 2023. EMBO Molecular Medicine. Dec 7:15(12):e17737. PMID: 37902007

Daneshdoust, et al. 2023. Cells. Sep 30:12(19):2338. PMID: 37830602

Wang, et al. 2023. Cell Bioscience. Dec 1:13(1):224. PMID: 38041134

Guillen, et al. 2022. Nature Cancer. Feb 3(2):232-250. PMID: 35221336

Related Tools for PDX models

Cat. # Tool Name
162069 HCI-001 breast cancer PDX Key Info View Tool
162070 HCI-002 breast cancer PDX Key Info View Tool
162071 HCI-003 breast cancer PDX Key Info View Tool
162077 HCI-009 breast cancer PDX Key Info View Tool
162080 HCI-012 breast cancer PDX Key Info View Tool

Related News

Representative example of haematoxylin and eosin staining of CRUK0935 T1-R5 TRACERx lung cancer PDX model at early P0 passage.
PDX Models

New non-small cell lung cancer (NSCLC) patient-derived-xenograft (PDX) models now available at CancerTools.org

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.